Plus Therapeutics, INC S-1 registration statements

Plus Therapeutics, Inc. filed an S-1MEF to increase its public offering of units and pre-funded units by an additional $2.875 million, bringing the total offering to $17.25 million.

Plus Therapeutics, a radiotherapeutics and diagnostics company, is launching a public offering of units and pre-funded units to raise capital, while navigating ongoing Nasdaq listing compliance challenges and advancing its cancer treatment pipeline.

Plus Therapeutics, Inc. filed an S-1 registration statement to register up to 33 million shares for resale by Lincoln Park Capital Fund, LLC, enabling access to up to $50 million in gross proceeds for working capital and general corporate purposes.

Plus Therapeutics, Inc. has entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing the company to sell up to $50 million of its common stock over 36 months, a move expected to cause substantial dilution to existing shareholders.

Plus Therapeutics, Inc. has filed an S-1 registration statement to register the resale of up to 17,000,000 shares of common stock to Lincoln Park Capital Fund, LLC, potentially raising up to $50 million in gross proceeds for working capital and general corporate purposes, while facing a 'going concern' qualification from its auditors.

Plus Therapeutics has filed an amendment to its S-1 registration statement, covering the resale of up to 10,774,596 shares of common stock by selling stockholders, potentially generating $19.25 million.

Plus Therapeutics has filed an S-1 registration statement for the resale of up to 10,774,596 shares of its common stock by selling stockholders.

Plus Therapeutics is planning a public offering of common stock and warrants to raise capital for working capital and general corporate purposes.